Literature DB >> 12533090

Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele.

Christian Enzinger1, Stefan Ropele, Siegrid Strasser-Fuchs, Peter Kapeller, Helena Schmidt, Birgit Poltrum, Reinhold Schmidt, Hans-Peter Hartung, Franz Fazekas.   

Abstract

BACKGROUND: In multiple sclerosis (MS), the epsilon4 allele of apolipoprotein E (APOE epsilon4) has been associated with more rapid clinical worsening and more severe tissue damage on magnetic resonance imaging.
OBJECTIVE: To use proton magnetic resonance spectroscopy ((1)H-MRS) to further explore the biochemical changes in the brains of patients with MS associated with APOE epsilon4.
DESIGN: A 2-year clinical and (1)H-MRS follow-up cohort study.
SETTING: The MS outpatient clinic, Department of Neurology, and Magnetic Resonance Center of Karl-Franzens University. PATIENTS: We performed (1)H-MRS of the central portion of both hemispheres and APOE genotyping in 72 patients (52 women and 20 men; mean +/- SD age, 34.8 +/- 8.8 years) with clinically definite relapsing-remitting MS. Repeated studies were performed in 44 patients after a mean +/- SD interval of 34 +/- 9 months. MAIN OUTCOME MEASURE: Levels of N-acetylaspartate as measured by (1)H-MRS.
RESULTS: Patients with MS and an epsilon4 allele (n = 19) had a significantly lower mean +/- SD N-acetylaspartate-creatine ratio than those without an epsilon4 allele (n = 53) (1.73 +/- 0.26 vs 1.89 +/- 0.24; P =.04) despite the absence of significant differences in age at onset, disease duration, Expanded Disability Status Scale score, and number of previous relapses between subgroups. During follow-up, the drop in the N-acetylaspartate-creatine ratio of epsilon4 carriers was also significantly larger (-0.31 vs -0.10; P =.01). This was paralleled by a higher number of relapses (mean +/- SD, 4.1 +/- 2.7 vs 1.7 +/- 1.6; P =.02) and a faster although nonsignificant progression of disability (mean +/- SD (Delta)Expanded Disability Status Scale score, 0.9 +/- 1.8 vs 0.3 +/- 1.1; P =.19).
CONCLUSIONS: The APOE epsilon4 allele has a negative effect on the course of MS, and increasing axonal damage may be an important mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12533090     DOI: 10.1001/archneur.60.1.65

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

Review 1.  New approaches to investigating heterogeneity in complex traits.

Authors:  R Bomprezzi; P E Kovanen; R Martin
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

2.  Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells.

Authors:  Stephen D Skaper; Massimo Barbierato; Laura Facci; Mila Borri; Gabriella Contarini; Morena Zusso; Pietro Giusti
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

3.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

Review 4.  Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Med Chem       Date:  2012-10-05       Impact factor: 7.446

5.  Global N-acetylaspartate declines even in benign multiple sclerosis.

Authors:  D J Rigotti; O Gonen; R I Grossman; J S Babb; A Falini; B Benedetti; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

Review 6.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

Review 7.  Imaging genetics of structural brain connectivity and neural integrity markers.

Authors:  Stefano Marenco; Eugenia Radulescu
Journal:  Neuroimage       Date:  2009-11-22       Impact factor: 6.556

Review 8.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 9.  AR, apoE, and cognitive function.

Authors:  Jacob Raber
Journal:  Horm Behav       Date:  2008-02-26       Impact factor: 3.587

10.  Polymorphism of Apo lipoprotein E gene and the risk of multiple sclerosis.

Authors:  Hamid Mirmohammad Sadeghi; Ali Mohammad Sabzghabaee; Zeinab Mousavian; Mohammad Saadatnia; Shahin Shirani; Fatemeh Moazen
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.